PMID- 23870382
OWN - NLM
STAT- MEDLINE
DCOM- 20140403
LR  - 20180305
IS  - 1476-4245 (Electronic)
IS  - 1475-4916 (Linking)
VI  - 102
IP  - 3
DP  - 2013 Jul
TI  - Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound 
      effect and similitude.
PG  - 215-24
LID - S1475-4916(13)00035-0 [pii]
LID - 10.1016/j.homp.2013.05.001 [doi]
AB  - BACKGROUND: Homeopathic treatment is based on the principle of similitude ('like 
      cures like') administering to sick individuals substances that cause similar 
      symptoms in healthy individuals, employing the paradoxical or biphasic action of 
      the organism as therapeutic response. This homeostatic, vital or secondary action 
      of the organism is scientifically explained by the rebound effect of drugs, 
      resulting in worsening of symptoms after enantiopathic treatment withdrawal. 
      Natalizumab reduces relapses in patients with active multiple sclerosis (MS), but 
      recent studies report severe worsening of MS after suspension of treatment, as a 
      consequence of the rebound effect. METHOD: Extending this source of evidence, 
      this work reviews research that demonstrates secondary worsening of MS after 
      discontinuation of natalizumab, a human monoclonal antibody that suppresses the 
      disease inflammatory activity as primary action. RESULTS: Several studies refer 
      to the immune reconstitution inflammatory syndrome (IRIS) as a plausible 
      explanation of reactivation of MS after withdrawal of natalizumab: a rebound 
      effect or secondary action of the organism in response to the primary 
      immunosuppression caused by the drug. CONCLUSION: Relapses of MS after 
      discontinuation of natalizumab treatment indicate rebound of disease activity, 
      supporting the homeopathic principle and warning healthcare professionals about 
      this serious iatrogenic event.
CI  - Copyright (c) 2013 The Faculty of Homeopathy. Published by Elsevier Ltd. All rights 
      reserved.
FAU - Teixeira, Marcus Zulian
AU  - Teixeira MZ
AD  - Department of Internal Medicine, Faculty of Medicine, University of Sao Paulo, 
      Sao Paulo, Brazil. marcus@homeozulian.med.br
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Homeopathy
JT  - Homeopathy : the journal of the Faculty of Homeopathy
JID - 101140517
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunologic Factors)
RN  - 0 (Natalizumab)
RN  - 143198-26-9 (Integrin alpha4)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*adverse effects
MH  - Homeopathy/*adverse effects
MH  - Humans
MH  - Immunologic Factors/administration & dosage/*adverse effects
MH  - *Integrin alpha4/immunology
MH  - Multiple Sclerosis/*drug therapy
MH  - Natalizumab
OTO - NOTNLM
OT  - Homeopathy
OT  - Immune reconstitution inflammatory syndrome
OT  - Law of similars
OT  - Multiple sclerosis
OT  - Natalizumab
OT  - Paradoxical reaction
OT  - Pharmacodynamic action of homeopathic remedy
OT  - Rebound effect
EDAT- 2013/07/23 06:00
MHDA- 2014/04/04 06:00
CRDT- 2013/07/23 06:00
PHST- 2012/06/12 00:00 [received]
PHST- 2013/01/15 00:00 [revised]
PHST- 2013/05/02 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/04/04 06:00 [medline]
AID - S1475-4916(13)00035-0 [pii]
AID - 10.1016/j.homp.2013.05.001 [doi]
PST - ppublish
SO  - Homeopathy. 2013 Jul;102(3):215-24. doi: 10.1016/j.homp.2013.05.001.